Champions Oncology Reports Record $59.4M Annual Revenue but $1.2M Net Loss
Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 4% from $56.9 million, for the year ended April 30, 2026. The company swung to a net loss of $1.2 million, compared with net income of $4.7 million a year earlier, as operating costs rose and the prior year's $4.5 million data license revenue did not recur.
Key points
- Fiscal 2026 oncology revenue was $59.4 million, up 4% from $56.9 million; the prior year included about $4.5 million of data license revenue that did not recur.
- Net loss was $1.2 million for fiscal 2026 versus net income of $4.7 million in fiscal 2025; adjusted EBITDA was $1.6 million versus $7.1 million.
- Fourth quarter revenue was $13.8 million, up 12% from $12.4 million, and the quarterly net loss narrowed to $667,000 from $1.8 million.
- Cash was $4.9 million at April 30, 2026, with no debt, down from $9.8 million a year earlier.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.